Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
The purpose of The PROSPECT Study is to evaluate an investigational medication for the
treatment of moderate to severe ulcerative colitis. This study is being conducted at up to 38
clinical research centers in the US, Canada, and Belgium, and is open to male and female
patients 12 years and older. Participants in the study will have a number of visits to a
research center over a five-month period. All study related care and medication is provided
to qualified participants at no cost: this includes all visits, examinations, and laboratory
work.